Does Tennessee Medicaid cover GLP-1s for weight loss?
Does Tennessee Medicaid cover GLP-1s for weight loss?
Tennessee Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: 18 and over: a BMI over 30, or over 27 with a weight-related comorbidity such as hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH or sleep apnea — documented in chart notes, not asserted. Under 18: at or above the 95th percentile for age and sex. Wegovy and Saxenda start at 12, Zepbound at 18. Those criteria are quoted from Clinical Criteria, Step Therapy, and Quantity Limits for the TennCare PDL, read directly rather than summarized from an aggregator. Last checked 2026-09-05.
What the prior authorization asks for
- BMI threshold
- 18 and over: a BMI over 30, or over 27 with a weight-related comorbidity such as hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH or sleep apnea — documented in chart notes, not asserted. Under 18: at or above the 95th percentile for age and sex. Wegovy and Saxenda start at 12, Zepbound at 18.
- Tried first
- Wegovy and Zepbound are preferred and need prior authorization. Saxenda and generic liraglutide are non-preferred: both need trial and failure of two preferred agents, and liraglutide additionally needs a clinically valid reason why brand Saxenda cannot be used. The prescriber must attest the patient is in a nutrition and lifestyle program, no other obesity drug may run alongside it, no second GLP-1 and no DPP-4 inhibitor, and a personal or immediate family history of medullary thyroid carcinoma or MEN2 rules it out.
- To keep it
- Renewal requires chart notes documenting a loss of at least 5% of baseline body weight — of baseline BMI-for-age under 18 — and continued participation in the lifestyle program. Someone who misses that can be approved for one more month to titrate off.
- Approval runs for
- 12 months, then a renewal request
TennCare's obesity criteria are no longer interim: the agents sit in the permanent PDL criteria document, which sets prior-authorization approvals at one year unless a drug's own entry says otherwise.
Both tools fill from these criteria rather than from a template — a prior authorization for Tennessee, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Tennessee decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Clinical Criteria, Step Therapy, and Quantity Limits for the TennCare PDL , effective 2026-09-01. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Tennessee can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.